ArticleCancers2024
Deferral of Treatment for Small Choroidal Melanoma and the Risk of Metastasis: An Investigation Using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO).
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Review
- Validation of MOLES score for small choroidal melanomas: impact of assuming enlargement for telemedicine in sizable lesions.Eye (London, England) · 2026Article
- Independent validation of time to treatment as a prognostic factor in uveal melanoma.BMC cancer · 2026Article
- Twelve reasons delays in uveal melanoma treatment might affect prognosis.The British journal of ophthalmology · 2025Article
- Higher AJCC stage at primary tumor diagnosis may predict shorter survival in metastatic uveal melanoma.Scientific reports · 2025Article
- Genetic landscape of uveal melanoma in Southeast Asia: high 1q gains and unique patterns of metastasis risk.Eye and vision (London, England) · 2025Article
- Insights into shape of uveal melanoma: a comprehensive evaluation of clinical features, pathological features, and prognosis analysis.Frontiers in medicine · 2025Article
- Expert Opinions on Uveal Melanoma: Insights from the 58th Ophthalmic Oncology Group Meeting.Ocular oncology and pathology · 2024Article
- On the Prognostic Implication of Delays in the Definitive Treatment of Uveal Melanoma.Cancers · 2024Article
- Article
- Growth of indeterminate choroidal melanocytic tumors: Time to malignant transformation.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe estimated metastatic-death risk when the treatment of small choroidal melanomas is deferred until growth is observed.
methodsIn 24 patients with choroidal melanoma (median diameter 5.85 mm), the exponential growth rate estimated by a mixed-effects model was 4.3% per year. Using the Liverpool Uveal Melanoma Prognosticator Online v.3 (LUMPO3), we measured changes in 15-year metastatic and non-metastatic death risks according to whether the tumor is treated immediately or after observing growth 4 or 12 months later, considering age, sex, and metastasis predictors.
resultsIn 40-year-old females with 10 mm, disomy 3 and monosomy 3 choroidal melanomas (prevalence 16%), the 15-year absolute risks of metastatic death are 4.2% and 76.6%, respectively, increasing after a 4-month delay by 0.0% and 0.2% and by 3.0% and 2.3% with tumor growth rates of 5.0% and 20.0%, respectively. With 12-month delays, these risks increase by 0.0% and 0.5% and by 1.0% and 7.1%, respectively. Increases in metastatic-death risk are less with smaller tumors and with a higher risk of non-metastatic death.
conclusionsDeferring treatment of choroidal melanomas until documentation of growth may delay iatrogenic visual loss by months or years and is associated with minimal increase in metastatic mortality, at least with small tumors with usual growth rates of up to 40% per year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.